1. Salti I, Bénard E, Detournay B, et al. A population-based study of diabetes and its

characteristics during the fasting month of Ramadan in 13 countries. Diabetes Care.

2004;27(10):2306-2311.

2. Hassanein M, Al-Arouj M, Hamdy O, et al. Diabetes and Ramadan: Practical guidelines

2021. Diabetes Res Clin Pract. 2022;185:109185.

3. American Diabetes Association. Standards of Care in Diabetes—2025. Diabetes Care.

2025;48(Suppl 1):S1-S350.

4. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2

diabetes, 2022. A consensus report by ADA and EASD. Diabetologia. 2022;65(12):1925-

1966.

115

2026 – FEVRAL

5. Babineaux SM, Toaima D, Boye KS, et al. Multi-country retrospective observational

study of the management and outcomes of patients with Type 2 diabetes during Ramadan

(CREED). Diabetes Res Clin Pract. 2015;109(2):231-242.

6. Hassanein M, Echtay A, Malek R, et al. Ramadan fasting and diabetes: DAR global

survey. Diabetes Res Clin Pract. 2017;126:303-316.

7. Azar ST, Echtay A, Wan Bebakar WM, et al. Efficacy and safety of lixisenatide versus

sulfonylurea during Ramadan. Diabetes Res Clin Pract. 2016;119:16-24.

8. Brady EM, Davies MJ, Gray LJ, et al. A randomized controlled trial comparing DPP-4

inhibitors and sulfonylurea during Ramadan. Diabet Med. 2014;31(11):1367-1373.

9. Bashier A, Khalifa AA, Abdelgadir EI, et al. Safety of SGLT2 inhibitors during

Ramadan fasting. Diabetes Res Clin Pract. 2018;137:219-226.

10.International Diabetes Federation. IDF Diabetes Atlas, 10th ed. Brussels: IDF; 2021.